"Double-Blind Method" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment.
| Descriptor ID |
D004311
|
| MeSH Number(s) |
E05.318.780.300 E05.581.500.300 N05.715.360.780.320 N06.850.520.445.300
|
| Concept/Terms |
Double-Blind Method- Double-Blind Method
- Double Blind Method
- Double-Blind Methods
- Method, Double-Blind
- Methods, Double-Blind
- Double-Masked Method
- Double Masked Method
- Double-Masked Methods
- Method, Double-Masked
- Methods, Double-Masked
- Double-Masked Study
- Double Masked Study
- Double-Masked Studies
- Studies, Double-Masked
- Study, Double-Masked
- Double-Blind Study
- Double Blind Study
- Double-Blind Studies
- Studies, Double-Blind
- Study, Double-Blind
|
Below are MeSH descriptors whose meaning is more general than "Double-Blind Method".
Below are MeSH descriptors whose meaning is more specific than "Double-Blind Method".
This graph shows the total number of publications written about "Double-Blind Method" by people in this website by year, and whether "Double-Blind Method" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 29 | 29 |
| 1997 | 0 | 31 | 31 |
| 1998 | 0 | 25 | 25 |
| 1999 | 0 | 31 | 31 |
| 2000 | 0 | 30 | 30 |
| 2001 | 0 | 39 | 39 |
| 2002 | 0 | 30 | 30 |
| 2003 | 0 | 39 | 39 |
| 2004 | 0 | 36 | 36 |
| 2005 | 0 | 44 | 44 |
| 2006 | 0 | 44 | 44 |
| 2007 | 0 | 45 | 45 |
| 2008 | 0 | 51 | 51 |
| 2009 | 0 | 49 | 49 |
| 2010 | 0 | 38 | 38 |
| 2011 | 0 | 58 | 58 |
| 2012 | 0 | 52 | 52 |
| 2013 | 0 | 47 | 47 |
| 2014 | 0 | 56 | 56 |
| 2015 | 0 | 45 | 45 |
| 2016 | 0 | 49 | 49 |
| 2017 | 0 | 53 | 53 |
| 2018 | 0 | 54 | 54 |
| 2019 | 0 | 63 | 63 |
| 2020 | 0 | 49 | 49 |
| 2021 | 0 | 50 | 50 |
| 2022 | 0 | 27 | 27 |
| 2023 | 0 | 25 | 25 |
| 2024 | 0 | 41 | 41 |
| 2025 | 0 | 51 | 51 |
| 2026 | 0 | 26 | 26 |
To return to the timeline,
click here.
Below are the most recent publications written about "Double-Blind Method" by people in Profiles.
-
Lumpectomy Margins and Local Recurrence in DCIS: Results From the NRG Oncology/NSABP B-35 Randomized Clinical Trial. JAMA Surg. 2026 09 01; 161(9):861-869.
-
Addition of High-Dose Vitamin D3 to Standard Treatment in Patients With Metastatic Colorectal Cancer: The SOLARIS Randomized Clinical Trial (Alliance A021703). JAMA. 2026 Sep 01; 336(9):746-754.
-
DNL343 and Disease Progression in Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial. JAMA Netw Open. 2026 Sep 01; 9(9):e2634809.
-
Effect of Vutrisiran According to Baseline Tafamidis Use in Transthyretin Amyloidosis With Cardiomyopathy: Insights From HELIOS-B. J Am Coll Cardiol. 2026 Sep 22; 88(12):1402-1412.
-
Natriuretic Peptide and Transthyretin and Their Relationship With Clinical Outcomes: Results From ATTRIBUTE-CM, a Randomized Controlled Trial. J Am Heart Assoc. 2026 Oct 06; 15(19):e050566.
-
ALG-055009 in non-cirrhotic adults with metabolic dysfunction-associated steatohepatitis (HERALD): a randomised, double-blind, placebo-controlled, phase 2a trial. Lancet Gastroenterol Hepatol. 2026 Nov; 11(11):984-996.
-
2'-Fucosyllactose Effects on Preterm Growth, Tolerance, and Neurobehavior: A Double-Blind, Randomized, Placebo-Controlled Pilot. Nutrients. 2026 Jul 26; 18(15).
-
Magrolimab Plus Azacitidine Versus Placebo Plus Azacitidine in Patients With Untreated Higher-Risk Myelodysplastic Syndromes: The Phase III ENHANCE Study. J Clin Oncol. 2026 09 10; 44(26):2529-2542.
-
Effect of moderate or high versus low dose daily vitamin D on COVID-19 incidence: A double-blind, parallel-group randomized clinical trial. Clin Nutr. 2026 Sep; 64:106722.
-
Differential impact of proton pump inhibitors and antibiotics on immunotherapy efficacy after chemoradiotherapy in locally advanced non-small-cell lung cancer: a post-hoc analysis of the PACIFIC trial. Lancet Oncol. 2026 Aug; 27(8):1043-1056.